Abdominal Chemo Increases Ovarian Cancer Survival Rate

A large clinical trial shows that chemotherapy given directly into the stomach as well as into a vein can improve the survival of women with advanced ovarian cancer by about sixteen months. The results of the study, which appear in this week's issue of the New England Journal of Medicine, prompted the National Cancer Institute to issue a statement supporting doctors to employ this plan of attack for appropriate patients. Did.

Increases Ovarian Cancer Survival Rate


A large clinical trial shows that chemotherapy given directly into the stomach as well as into a vein can improve the survival of women with advanced ovarian cancer by about sixteen months. The results of the study, which appear in this week's issue of the New England Journal of Medicine, prompted the National Cancer Institute to issue a statement supporting doctors to employ this plan of attack for appropriate patients. Did.

 

Why is this new treatment so important? Ovarian cancer is the fourth leading cause of cancer deaths in women, affecting more than 22,000 women in 2005 and killing more than 16,000. Although the disease is treatable if detected early, almost all cases go unnoticed until they have progressed beyond limits. Ovary. Since many ovarian cancer patients are diagnosed at a later stage, it is important to find better treatment methods for advanced disease.

 

What is already known about ovarian cancer? Almost all women with advanced ovarian cancer are given chemotherapy followed by surgery to get rid of the tumor. Chemotherapy is usually given into a vein and reaches the tumor cells in the abdomen through the bloodstream. Doctors have also experimented with delivering chemotherapy directly into the abdomen through a catheter, a system called intraperitoneal (IP) chemotherapy. Eight clinical trials of this approach have been conducted, and most have shown benefit over IP chemotherapy. But according to the study's author, Deborah Armstrong, MD, this technique is not widely used.

 

"There has been a predisposition against IP treatment in ovarian disease since it's an old thought, it requires expertise and involvement in medical procedure and chemotherapy, and it's IV," said Armstrong, a clinical oncologist and partner. "is extra confounded than chemotherapy." Teacher at the John Hopkins Kimmel Malignant growth Community in Baltimore.

 

How the study was conducted: Women with stage III ovarian cancer were randomly assigned to receive either standard chemotherapy in the vein (210 women), or a combination of chemotherapy in the vein and IP chemotherapy (205 women). The women had already had surgery in which all or most of the tumor was successfully removed; None had residual tumor that was larger than 1 cm in diameter. All women were treated with the same drug, cisplatin and paclitaxel. Six cycles of chemotherapy were planned for both groups.

 

what did you get? Women who had IP chemo operated longer without their cancer coming back and lived the longest overall. Women who received conventional chemotherapy into a vein lived about 4 years after treatment, while women who received chemotherapy into the stomach as well as an abdominal vein lived about five and a half years after treatment.

 

Stephen A. The improvement is "one of the largest benefits ever seen for a new therapy in gynecologic oncology," based on the data from Cannistra, MD, who wrote an editorial published with the study. He is a professor at Harvard Medical School and managing director of the division of gynecologic medical oncology at Beth Israel Deaconess Medical Center in Boston.

 

However, IP treatment was much more difficult for patients. Women who took this treatment had several additional terrible or life-threatening side effects, including low white blood cell counts, infections, fatigue, and pain. Many side effects were associated with the catheter that must be inserted into the abdomen to deliver chemotherapy. These problems were so severe that less than half of the women designated to undergo IP chemotherapy completed all six designed treatment cycles. “This prolongs survival significantly,” Cannistra wrote.

 

Women who received IP therapy reported significantly worse quality of life during and immediately after treatment. Yet, after a year, both groups described similar quality of life.

 

FAQs

Is cancer cured after chemo?

Chemotherapy drugs help kill cancer cells and in many cases, such as blood cancer, it helps cure the cancer completely.

 

 

What are the chances of surviving ovarian cancer?

For all types of ovarian cancer combined, about 78% of people with ovarian cancer survive for at least 1 year after diagnosis. More than 60% of patients survive for at least 3 years after diagnosis, and more than 50% of ovarian cancer patients survive for at least 5 years after diagnosis.

 

 

Has anyone recovered from ovarian cancer?

About 20% of women with advanced stage ovarian cancer survive for 12 years after treatment and are effectively cured.

 

How long is the treatment for ovarian cancer?

For ovarian cancer, the drugs are usually given in repeated cycles over 4–5 months, but this can vary.

 

How long can chemo extend life?

For many metastatic tumors, even if incurable, survival with chemotherapy and best treatment is now more than a year and often much longer. Colorectal cancer survival often exceeds 24 months, with 10% of patients surviving more than five years.

 

 

How long does it take to recover after chemo?

Return to normal is common, but it takes some time – usually six months or more. “Individuals who have done chemo are at long last back to ordinary," Patricia said. “Breast cancer treatment can take a full year, but six months after it's over, life comes back – the incisions have healed, the hair grows back, the brain fog from chemo goes away."

No comments:

Post a Comment

 

Copyright (c) 2025 Servmanglam All Right Reseved